Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2013

View Archived Issues

Velocity Pharmaceutical Development announces collaboration and VPD-737 IND

Tyrosine-protein kinase inhibitors disclosed by Daiichi Sankyo

Novel Bcl-2 inhibitors reported by French researchers

Ambra-1 expression is linked to NRAS/BRAF mutational status in melanoma

MacroGenics doses first patient in phase I MGA-271 trial

OSI Pharmaceuticals presents new compounds with promise in ovarian cancer models

BYM-338 receives FDA breakthrough therapy designation

Adimab establishes new collaborations with Innovent and Celgene

Varinel synthesizes novel iron chelators for neurodegenerative disorders

Novel hRAD51 protein expression inhibitors disclosed by Eisai

Otonomy's OTO-201 reduces treatment failure in subjects undergoing ear tube placement surgery

Toray Industries divulges new SEH inhibitors for hypertension

DiaMedica enrolls final patient in DM-199 clinical trial

Eisai files petition in federal court seeking DEA scheduling of Fycompa

FDA grants orphan drug designation to Alnylam's RNAi therapeutic for hemophilia A

RedHill completes European regulatory meetings for Crohn's disease therapeutic

Mutations in TGF-beta predispose to allergic phenotypes in humans

Oncopeptides commences phase II study of melflufen in multiple myeloma

PDI signs agreement to commercialize molecular diagnostic tests

Membrane active chelators for the treatment of malaria and African trypanosomiasis

FDA grants orphan drug status to dantrolene sodium

Australian team prepares new L-type calcium channel compounds

Orphan drug status granted to deflazacort

FDA grants orphan drug status for ruxolitinib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...